1. Alkermes will participate in a panel on Orexin Receptor Agonist development. 2. The discussion focuses on treatments for sleep-wake disorders. 3. Event is part of the 24th Annual Needham Virtual Healthcare Conference. 4. Alkermes has a strong pipeline in neurological disorder treatments. 5. Company continues to position itself in innovative neuroscience medicines.
Engagement in medical discussions highlights Alkermes' commitment and innovation in therapeutics. Similar past events have positively influenced stock prices of biotech firms, showcasing investor confidence.
The webcast is essential for investors tracking advancements in Alkermes' pipeline, potentially driving interest. However, without additional clinical trial data or announcements, the immediate impact may be moderate.
Immediacy of the webcast allows for quick dissemination of potential new insights. Historically, short-term spikes in interest have followed such conferences for biotech companies.
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a webcast panel discussion "Development of Orexin Receptor Agonist in Sleep-Wake Disorders" at the upcoming 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 11:45 a.m. EDT (4:45 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Jamie Constantine
Investor Relations
+1 781 873 2402
SOURCE Alkermes plc